account_id none on file
legal_name Solid Biosciences Inc.
ticker SLDB
cik 1707502
domain solidbio.com
linkedin_company_url https://www.linkedin.com/company/solid-biosciences
entry_point_account_id none on file
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 10 executives 3 family 0
why_nownone on file
callsnone on file
filings
General and administrative expenses also include legal fees relating to patent and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel expenses, and facility-related expenses.
filing / Aug 6, 2026 / receipt
• costs of outside consultants engaged to assist in our research and development activities, including their fees, equity-based compensation and related travel expenses;
filing / Aug 6, 2026 / receipt
In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs.
filing / Aug 6, 2026 / receipt
If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and Candidates outside of the United States, which could limit our growth potential and increase our development costs.
filing / Aug 6, 2026 / receipt
The continuing efforts of the government, insurance companies, managed care organizations and other health care payors to contain or reduce costs of health care may adversely affect:
filing / Aug 6, 2026 / receipt
General and administrative expenses also include legal fees relating to patent and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel expenses, and facility-related expenses.
filing / May 12, 2026 / receipt
• costs of outside consultants engaged to assist in our research and development activities, including their fees, equity-based compensation and related travel expenses;
filing / May 12, 2026 / receipt
In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs.
filing / May 12, 2026 / receipt
If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and Candidates outside of the United States, which could limit our growth potential and increase our development costs.
filing / May 12, 2026 / receipt
The continuing efforts of the government, insurance companies, managed care organizations and other health care payors to contain or reduce costs of health care may adversely affect:
filing / May 12, 2026 / receipt
executives
| Alexander (Bo) Cumbo | President and Chief Executive Officer | - | receipt |
| Ian Smith | Chairman of the Board | - | receipt |
| Kevin Tan | Chief Financial Officer | - | receipt |
familynone on file
upcoming
| 2026-11-02 | earnings call | scheduled | ir |
changes
| 2023-01-09 | Chief Financial Officer, appointed | sec_8k |
| 2022-12-05 | Chief Executive Officer, departed | sec_8k |
| 2022-12-05 | President and Chief Executive Officer, appointed | sec_8k |
| 2022-09-30 | Chief Executive Officer, departed | sec_8k |
| 2020-06-18 | Chairman of the Board, appointed | sec_8k |
mcp_package_hint
slug solid-biosciences-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$